Skip to main content

Table 5 Affordability of orphan drugs in China

From: The availability and affordability of orphan drugs for rare diseases in China

Generic name (Brand name)

Median Unit PriceA (USD)

Daily Dose

Duration of Treatment Course (days)

Total Course Cost (USD)

Days of per capita net income

Coverage of NBMI (Y/N)

Affordability (if 5 % OOP)

Urban Resident

Affordability

Rural Resident

Affordability

Ave (Y/N)

Urban High (Y/N)

Ave3

High4

Y/N

Ave

High

Y/N

Recombinant human coagulation factor VII (Kogenate FS)

0.85/IU

1750 IU

2

2961.5

309.1

114.6

N

967.8

401.8

N

Y, Part B

N

N

Recombinant human coagulation factor VIIa (NovoSeven)B

869.02/mg

50.4 mg

1

43798.7

4571.9

1695.0

N

14313.3

5942.8

N

N

N

N

Bosentan (Tracleer)

0.75/mg

250 mg

28

5272.4

550.4

204.0

N

1723.0

715.4

N

N

N

N

Iloprost (Ventavis)

4.38/ug

50ug

28

6129.5

639.8

237.2

N

2003.1

831.7

N

N

N

N

Somatropin (Saizen)

10.89/IU

7 IU

28

2134.3

222.8

82.6

N

697.5

289.6

N

N

N

N

Busulfan (Busulfex)

4.66/mg

224 mg

4

4178.5

436.2

161.7

N

1365.5

567.0

N

Y, Part B

N

N

Imatinib (Glivec)

0.32/mg

600 mg

28

5384.6

562.1

208.4

N

1759.7

730.6

N

N

N

N

Imatinib (Glivec)

0.32/mg

600 mg

28

5438.5

567.7

210.5

N

1777.3

737.9

N

N

N

N

Nilotinib (Tasigna)

0.26/mg

800 mg

28

5779.5

603.3

223.7

N

1888.7

784.2

N

N

N

N

Teniposide (Vumon)

0.56/mg

102 mg

5

286.1

29.9

11.1

N

93.5

38.8

N

N

N

Y

Arsenious acid (Yitaida)

2.32/mg

10 mg

28

650.6

67.9

25.2

N

212.6

88.3

N

Y, Part B#

N

N

Rituximab (MabThera)

6.1/mg

91.1 mg

28

15558.2

1624.0

602.1

N

5084.4

2111.0

N

N

N

N

Sorafenib tosylate (Nexavar)

0.33/mg

800 mg

28

7502.6

783.2

290.3

N

2451.8

1018.0

N

N

N

N

Poractant alfa (Curosurf)C

4.8/mg

525 mg

1

2456.7

256.4

95.1

N

802.8

333.3

N

Y, Part B

N

N

Human coagulation factor VII

0.3/IU

1750 IU

2

1065.7

111.2

41.2

N

348.3

144.6

N

Y, Part A

N

N

Human prothrombin complex concentrate

0.15 IU

3150 IU

2

969.2

101.2

37.5

N

316.7

131.5

N

Y, Part B#

N

N

Danazol

0.004/mg

600 mg

28

61.9

6.5

2.4

N

20.2

8.4

N

Y, Part B

Y

Y

Recombinant human growth hormone

3.7/IU

7 IU

28

725.6

75.7

28.1

N

237.1

98.5

N

Y, Part B

N

N

Teniposide

0.44/ mg

102 mg

5

223.1

23.3

8.6

N

72.9

30.3

N

Y, Part B

N

Y

Mitoxantrone

1.24/mg

10.2 mg

4

50.6

5.3

2.0

N

16.5

6.9

N

Y, Part B

Y

Y

Riluzole

0.16/mg

100 mg

28

453.2

47.3

17.5

N

148.1

61.5

N

N

N

Y

Riluzole

0.11/mg

100 mg

28

309.6

32.3

12.0

N

101.1

42.0

N

N

N

Y

Homoharringtonine

0.75/mg

2.5 mg

5

9.4

0.98

0.4

Y

3.1

1.3

N

Y, Part A#

Y

Y

Average

--

--

17.2

4843.5

505.6

187.4

--

1582.8

657.2

--

--

--

--

  1. 1.C/T: capsules/tablets, Inj: injection, Inh: inhalants. 2. In the calculations, we used the following average values: adult weight at 70 kg, children 15 kg, baby 1.5 kg; the body surface area at 1.7 m2. A: Use the minimum specifications as the standards about the investigated drugs. Translated the price and took the median values as analysis objects; B: Recommended dose is 90ug/kg, 8times a day. C: Birth weight used was 1.5 kg. The first dose is 150 mg/kg; repeat dose is 100 mg/kg, only one day usage. 3. “Ave”: a resident with per capita net income of average income households. 4. “High”: a resident with per capita net income of highest income households. Y=Yes N=No. “NBMI”: National Basic Medical Insurance. “Part A” or “Part B” means a drug is covered by the Part A or Part B drug list of National Basic Medical Insurance. “OOP”: out-of-pocket expenses. “#”: a drug is a national essential medicine of China
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172